TACTICAL THERAPEUTICS,INC

Tactical Therapeutics, Inc, a Delaware Corp formed in 2005, has developed a patented cancer therapeutic, Carboxyamidotriazole Orotate (CTO), as an Orphan drug to treat glioblastoma (GBM), malignant gliomas, brain metastases and different types of resistant solid cancers with different mutations. The business model is virtual with full time CEO and part-time management team, and highly distinguished and experienced Scientific Advisors and Consultants, some since 2005. Company Strategy is to carry our tasks for which expertise is available inhouse, and to outsource rest to qualified expert service providers, e.g., Pre-clinical and clinical work has been outsourced to highly reputable Clinical Research Organizations, Clinical Manufacturing Organizations, and Regulatory Consultants. The Intellectual Property comprises 8 issued United States Patents and 75 International Patents lasting through 2040. This work has been done inhouse. Competitive Advantages: The Clinical Development Program for GBM and other brain cancers has Compelling Competitive Advantages: - CTO has differentiated against other drugs- it is oral, safe, crosses the blood brain barrier, shows efficacy, and overcomes resistance. - Closely monitoring Phase I/II/III trials listed in ClinicalTrials.gov. Several Phase III trials have failed and been stopped for not meeting clinical endpoints. CTO offers Unique Value Proposition, since randomized Phase II trials are designed for Fast Track Approval, in 2025. Tactical Therapeutics is seeking a strategic partner to participate in the development and commercialization of the company’s lead product, CTO

网站

https://www.tacticaltherapeutics.com

TACTICAL THERAPEUTICS,INC的外部链接

所属行业

生物技术

规模

2-10 人

总部

New York，NY

类型

私人持股

创立

2005

领域

Oncology、COVID-19和Age-related Macular Degeneration